NCT02920931已完成1 期
A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Maximum observed concentration(Cmax) of Tenofovir
研究概览
简要总结
A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subject, aged 19- 45 years at screening.
- •Body weight of ≥ 55 kg and within ± 20% of ideal body weight (IBW)(kg) = {height (cm) - 100} * 0.9
- •No morbid symptom or sign, based on physical examination, with no innate or chronic disease.
- •Subject that is considered appropriate for participating in the study by an investigator, based on clinical laboratory test (hematology, clinical chemistry, urinalysis) that is performed according to the characteristics of investigational drugs.
- •Subjects must be able to listen to and understand the detailed statement of informed consent, and willing to decide to participate in the study, follow the study directions and provide written informed consent.
排除标准
- •A clinically significant disease or history in hepatobiliary system, kidney, digestive system, respiratory system, hemato-oncological system, endocrine system, neuro-psychiatric system, musculo-skeletal system, immune system, otorhinolaryngological system or cardiovascular system.
- •A history of gastrointestinal system disorder(i.e, Crohn's disease, ulcer, acute or chronic pancreatitis) or surgery (excluding simple appendectomy or herniorrhaphy) that may affect absorption of investigational drugs.
- •A history of hypersensitivity to investigational drugs and its additives or clinically significant hypersensitivity to any other drug.
- •Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption and any other hereditary disorder.
- •Vital sign measured in sitting position meets any one of following results; systolic blood pressure > 140 mmHg or <100 mmHg, diastolic blood pressure > 90 mmHg or <60 mmHg, pulse ≥ 100 times/min.
- •Aspartate aminotransferase(AST) or Alanine aminotransaminase(ALT) > 2 times upper normal limit, or Total bilirubin > 2 times upper normal limit.
- •Renal disorder (Creatinine clearance < 50 mL/min, calculated by Cockcroft-Gault formula)
- •Positive in serologic tests (RPR Ab(VDRL), HBsAg, hepatitis C virus (HCV) Ab, anti HIV(AIDS))
- •History of drug abuse, or positive in drug screening test.
- •Use of inducer or inhibitor of metabolic enzymes for drugs like barbiturate.
- •Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to the first administration of investigational drug, and this will affect this study or the safety of the subjects at discretion of study investigator.
- •Participation in another clinical trial or a bioequivalent study within 3 months prior to the first administration of investigational drug (The finish time of previous study is the day of the last administration of study drug)
- •Whole blood donation within 2 months or component donation within 1 month, prior to the first administration of investigational drug, or transfusion within 1 month prior to the first administration of investigational drug.
- •Prolonged excessive alcohol consumption (>21 units/week, 1 unit=10g of pure alcohol), or subjects who can not abstain from drinking from 24 hours prior to hospitalization until the discharge.
- •Smoking more than 10 cigarettes per day, excessive caffeine consumption (example: instant coffee > 5 cups/day)
- •Subjects planning to get a dental treatment(tooth extraction, orthodontic treatment, endodontic treatment etc) and a selective surgery(aesthetic surgery, LASIK, LASEK etc) during the period from informed consent form(ICF) to post-study visit, which is impossible to be postponed.
- •Subjects who are judged to be inappropriate for this study by investigators according to other reasons including clinical lab test result
研究组 & 干预措施
A
Experimental
- st period: Tenofovir disoproxil fumarate
- nd period: Tenofovir Disoproxil
干预措施: Tenofovir disoproxil (Drug)
B
Active Comparator
- st period: Tenofovir disoproxil
- nd period: Tenofovir Disoproxil fumarate
干预措施: Tenofovir disoproxil (Drug)
结局指标
主要结局
Maximum observed concentration(Cmax) of Tenofovir
时间窗: 0~72 hour after medication
Area under the curve(AUCt) of Tenofovir
时间窗: 0~72 hour after medication
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male VolunteersHealthyNCT02902523Huons Co., Ltd.50
已完成
1 期
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/RosuvastatinHypertensionHyperlipidemiaNCT02569814Boryung Pharmaceutical Co., Ltd100
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy SubjectsHepatitis BNCT04906109Dong-A ST Co., Ltd.96
已完成
1 期
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.HealthyNCT04322266Hanmi Pharmaceutical Company Limited61
已完成
1 期
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.HealthyNCT05191563Hanmi Pharmaceutical Company Limited56